Top Medical Searches

Marathon pauses Duchenne drug launch amid price outcry

Marathon Pharmaceuticals LLC said on Monday it was “pausing” the launch of its Duchenne muscular dystrophy drug after U.S. lawmakers questioned why the company priced it at $89,000 a year when patients had been able to import it for as little as $1,000. In a statement posted on the patient advocacy website Cure Duchenne, Marathon’s chief executive, Jeffrey Aronin, said the company was pausing the launch amid “concerns about how the pricing and reimbursement details will affect individual patients and caregivers.” The company said it would maintain its “expanded access program” under which 800 patients currently receive the drug for nothing. The furore is the latest in a series related to U.S. drug prices, including Mylan NV’s emergency EpiPen allergy treatment, that have drawn the ire of patients and lawmakers of all political stripes. Read More..

Be Sociable, Share!
February 13th, 2017 Posted in Drug
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us